Absence of Influence of Concomitant Administration of Rabeprazole on the Pharmacokinetics of Tacrolimus in Adult Living-donor Liver Transplant Patients: A Case-Control Study

DOI Web Site Web Site PubMed 被引用文献3件 参考文献47件

この論文をさがす

抄録

   This study assesses the effects of rabeprazole on the pharmacokinetics of tacrolimus, considering the cytochrome P450 (CYP) 2C19 and CYP3A5 genotypes of living-donor liver transplant patients (native intestine) and their corresponding donors (graft liver). We examined the concentration/dose ratio of tacrolimus in transplant patients treated with (n=17) or without (n=38) rabeprazole at 10 mg/day on postoperative days 22-28. A stratified analysis revealed no significant differences between the control and rabeprazole groups in the median (range) concentration/dose ratio of tacrolimus [(ng/mL)/(mg/day)] for CYP2C19 extensive/intermediate metabolizers [2.71 (1.00-6.15) versus 2.55 (0.96-9.25); P=0.85] and for poor metabolizers [4.92 (2.44-7.00) versus 3.82 (2.00-7.31); P=0.68], respectively. Even based on the classification of CYP2C19 genotypes of donors, no significant difference in the concentration/dose ratio of tacrolimus was found for the two groups (CYP2C19 extensive/intermediate metabolizers, P=0.52; poor metabolizers, P=0.51). The same was observed for CYP3A5*1 carriers (P=0.97 for native intestine; P=0.87 for graft liver) and CYP3A5*3/*3 carriers (P=0.89 for native intestine; P=0.56 for graft liver). These findings suggest a safer dosing and monitoring of tacrolimus coadministered with rabeprazole early on after liver transplantation regardless of the CYP2C19 and CYP3A5 genotypes of transplant patients and their donors.<br>

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (47)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ